Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin Sodium Blausiegel vs APP for VTE Prophylaxis
NCT00912483Phase 3Withdrawn
- Sponsor
- Azidus Laboratories Limited
- Start
- May 2010
- Primary completion
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of heparin in venous thromboembolism (VTE) (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoint: Incidence of venous thromboembolism at 28 days. Planned start May 2010; status: withdrawn.
02
Drugs
heparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00912483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912483.